Life
FDA Reconsiders Injectable Peptide Compounding Regulations
The FDA's potential shift on injectable peptide compounding could reshape industry practices, previously hindered by safety concerns. The ongoing conflict in Iran is also affecting trial recruitment.
Editorial Staff 5 days ago